<DOC>
	<DOCNO>NCT00929669</DOCNO>
	<brief_summary>The purpose study determine administration pasireotide LAR one year three patient gonadotroph adenomas elevate serum FSH concentration reduce serum follicle-stimulating hormone ( FSH ) normal reduce adenoma size .</brief_summary>
	<brief_title>Effect Pasireotide Long Acting Release ( LAR ) Gonadotroph Adenomas</brief_title>
	<detailed_description>Gonadotroph adenoma common pituitary macroadenomas . Currently medical treatment find decrease size adenoma , surgery treatment . The reason think pasireotide might affect gonadotroph adenoma pasireotide bind avidly somatostatin subtype 5 receptor , gonadotroph adenoma express receptor . For study , three subject gonadotroph adenoma , judge macroadenoma pituitary elevate serum FSH concentration , treat long-acting form pasireotide month one year . The effect pasireotide size adenoma determine MRI , FSH secretion judge serum concentration .</detailed_description>
	<mesh_term>Adenoma</mesh_term>
	<criteria>gonadotroph adenoma visual impairment attributable adenoma radiation therapy active gallbladder disease uncontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>pituitary tumor</keyword>
	<keyword>endocrine</keyword>
</DOC>